Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Exelixis
EXEL
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$26.36
0
0.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Get Report
Comment
Exelixis (EXEL) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Exelixis (NASDAQ:EXEL) Stock
Exelixis Stock (NASDAQ: EXEL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, September 20, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Thursday, September 19, 2024
UBS Initiates Coverage On Exelixis with Neutr...
Benzinga Newsdesk
Wednesday, September 18, 2024
A Closer Look at 5 Analyst Recommendations For Exelixis
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Exelixi...
Benzinga Newsdesk
Monday, September 16, 2024
Exelixis Announces Final Results From Phase 3...
Benzinga Newsdesk
Reported Sunday, Exelixis Presents Final Phas...
Benzinga Newsdesk
Thursday, August 08, 2024
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
Benzinga Insights
Truist Securities Reiterates Buy on Exelixis,...
Benzinga Newsdesk
Wednesday, August 07, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Vandana Singh
RBC Capital Reiterates Outperform on Exelixis...
Benzinga Newsdesk
Exelixis shares are trading higher after the ...
Benzinga Newsdesk
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Shanthi Rexaline
Tuesday, August 06, 2024
Exelixis Sees 2024 Total Revenues $1.975B-$2....
Benzinga Newsdesk
Exelixis shares are trading higher after the ...
Benzinga Newsdesk
Exelixis Q2 2024 Adj. EPS $0.84 Beats $0.30 E...
Benzinga Newsdesk
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
Piero Cingari
Exelixis Announces U.S. FDA Accepted The Supp...
Benzinga Newsdesk
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
Shanthi Rexaline
Tuesday, July 30, 2024
Oppenheimer Maintains Outperform on Exelixis,...
Benzinga Newsdesk
Friday, May 31, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
Avi Kapoor
Friday, May 24, 2024
Director At Exelixis Sells $576K Of Stock
Benzinga Insights
Monday, May 20, 2024
Exelixis Settles With Cipla To Resolve Two Pa...
Benzinga Newsdesk
Tuesday, May 14, 2024
Stephens & Co. Initiates Coverage On Exelixis...
Benzinga Newsdesk
Friday, May 10, 2024
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Vandana Singh
Friday, May 03, 2024
HC Wainwright & Co. Reiterates Buy on Exelixi...
Benzinga Newsdesk
Wednesday, May 01, 2024
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Benzinga Insights
TD Cowen Maintains Buy on Exelixis, Raises Pr...
Benzinga Newsdesk
Exelixis shares are trading lower after the c...
Benzinga Newsdesk
Tuesday, April 30, 2024
Exelixis Maintains FY24 Financial Guidance, T...
Benzinga Newsdesk
Exelixis shares are trading lower after the c...
Benzinga Newsdesk
Exelixis Q1 2024 Adj EPS $0.17 Misses $0.24 E...
Benzinga Newsdesk
Thursday, April 11, 2024
Exelixis shares are trading lower after Barcl...
Benzinga Newsdesk
Barclays Downgrades Exelixis to Equal-Weight,...
Benzinga Newsdesk
Wednesday, April 10, 2024
What Analysts Are Saying About Exelixis Stock
Benzinga Insights
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, February 23, 2024
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Avi Kapoor
Wednesday, February 07, 2024
RBC Capital Maintains Outperform on Exelixis,...
Benzinga Newsdesk
Tuesday, February 06, 2024
Recap: Exelixis Q4 Earnings
Benzinga Insights
Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimat...
Benzinga Newsdesk
Earnings Scheduled For February 6, 2024
Benzinga Insights
Monday, February 05, 2024
Earnings Preview For Exelixis
Benzinga Insights
Friday, February 02, 2024
Stifel Maintains Hold on Exelixis, Raises Pri...
Benzinga Newsdesk
Tuesday, January 30, 2024
Breaking Down Exelixis: 7 Analysts Share Their Views
Benzinga Insights
Barclays Maintains Overweight on Exelixis, Ra...
Benzinga Newsdesk
Thursday, January 25, 2024
Exelixis Announces Detailed Results Of Phase ...
Benzinga Newsdesk
Tuesday, January 23, 2024
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Vandana Singh
Monday, January 22, 2024
Bristol-Myers Squibb Announced Opdivo In Combination With Cabometyx Demonstrates Long-term Survival Benefits After Four Years Of Follow-up In The Checkmate -9er Trial In First-line Advanced Renal Cell Carcinoma
Charles Gross
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch